IL3RA and acute myeloid leukemia: In a planned, but not yet underway, clinical trial (NCT05574608), 12 patients with relapsed/refractory AML will receive fludarabine and cyclophosphamide chemotherapy followed by infusion of CD123-CAR-NK cells.